Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine sublingual film - Sumitomo Pharma America

Next Previous
Drug Profile

Apomorphine sublingual film - Sumitomo Pharma America

Alternative Names: APL-130277; Apomorphine HCI; Apomorphine HCI sublingual film; Apomorphine Hydrochloride Sublingual Thin Film; KYNMOBI

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adagio Pharmaceuticals
  • Developer Sumitomo Pharma America
  • Class Analgesics; Antiparkinsonians; Aporphines; Catechols; Erectile dysfunction therapies; Heterocyclic compounds; Phenanthrenes; Piperidines; Quinolines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Dopamine D2 receptor agonists; Heat shock transcription factor stimulants; NF-E2-related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 07 Jan 2026 Launched for Parkinson's disease in United Kingdom (Sublingual)
  • 05 Mar 2024 Discontinued - Registered for Parkinson's disease in Canada (Sublingual)
  • 05 Mar 2024 Withdrawn for Parkinson's disease in USA (Sublingual)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top